stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Revenue growth
Travere Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was 49.4%, down 61.1 percentage points from fiscal 2025 (110.5%). Over the past ten years it has ranged from −33.5% (fiscal 2021) to 254.2% (fiscal 2015); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 6.76% and above the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 110.5% | 49.90 |
| FY2024 | 60.6% | 27.86 |
| FY2023 | 32.7% | 49.66 |
| FY2022 | −17.0% | 16.55 |
| FY2021 | −33.5% | (46.63) |
| FY2020 | 13.1% | 6.36 |
| FY2019 | 6.75% | 0.74 |
| FY2018 | 6.01% | (9.97) |
| FY2017 | 16.0% | (17.76) |
| FY2016 | 33.7% | (220.45) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 36.2% | (11.95) |
| Jun 2026 | 48.2% | (7.46) |
| Mar 2026 | 55.6% | (17.78) |
| Dec 2025 | 73.4% | (88.70) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 59.6% |
| TVTX Travere Therapeutics, Inc. | 49.4% |
| DNTH Dianthus Therapeutics, Inc. compare | −11.7% |
| CRSP CRISPR Therapeutics AG compare | −34.3% |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement